

## TABLE OF CONTENTS

### **PLENARY SESSION**

<b>Nathan B. Eddy Award Introduction</b> .....	1-2
<i>M.W. Adler</i>	
<b>Nathan B. Eddy Award Lecture</b> .....	3-22
<i>M.J. Kreek</i>	
<b>SYMPOSIUM I</b> .....	23-25
<b>Recent Advances on Inhalant Abuse</b> <i>S.L. Cruz and R.L. Balster, Chairpersons</i>	
<b>SYMPOSIUM II</b> .....	26-27
<b>The Intersection of Drug Treatment and the Criminal Justice System</b> ..... <i>M. Iguchi and H. Kleber, Chairpersons</i>	
<b>SYMPOSIUM VI</b> .....	28-31
<b>New Approaches to Non-Addictive Analgesics</b> .....	
<i>W.K. Schmidt and F. Porreca, Chairpersons</i>	
<b>SYMPOSIUM VII</b> .....	32-35
<b>Taking it to the Streets: Contingency Management for Real-Life Drug Abuse Treatment</b> .....	
<i>L. Amass and M. Y. Iguchi, Chairpersons</i>	
<b>SYMPOSIUM VIII</b> .....	36-40
<b>Pharmacology and Clinical Potential of Delta Opioid Agonists</b> .....	
<i>S.S. Negus and F. Porreca, Chairpersons</i>	
<b>SYMPOSIUM XI</b> .....	41-43
<b>A Stone Unturned: The Promise of CABAergic Modulation in Cocaine Dependence Treatment</b> .....	
<i>A.R. Childress and D.C.S. Roberts, Chairpersons</i>	
<b>SYMPOSIUM XII</b> .....	44-46
<b>Basic and Clinical Pharmacology of Selective Cannabinoid Receptor (CB1 and CB2) Antagonists</b> .....	
<i>S. Heishman and B.R. Martin, Chairpersons</i>	
<b>SYMPOSIUM XIII</b> .....	47-50
<b>Allelic Polymorphism of Human Opioid Receptors: Functional Studies</b> .....	
<i>K.S. LaForge and M.J. Kreek, Chairpersons</i>	
<b>SYMPOSIUM XIV</b> .....	51-53
<b>Developmental Follow-up of Prenatal Drug Exposure in Pre-School and School-Aged Children</b> .....	
<i>L.P. Finnegan and V.L. Smeriglio, Chairpersons</i>	

<b>SYMPOSIUM XV</b>	
<b>Emerging Biological Targets for the Treatment of     Nicotine Dependence.....</b>	<b>54-56</b>
<i>R.S. Mansbach and L.P. Dwoskin, Chairpersons</i>	
<b>SYMPOSIUM XVI</b>	
<b>From Caffeine to Opiates: Novel Interventions for Substance     Use in Pregnancy .....</b>	<b>57-59</b>
<i>D. Svikis and L. Finnegan, Chairpersons</i>	
<b>ORAL COMMUNICATIONS I .....</b>	<b>60-63</b>
<b>Sex and the Single Drug</b>	
<b>ORAL COMMUNICATIONS II .....</b>	<b>63-66</b>
<b>The Brain in Pain</b>	
<b>ORAL COMMUNICATIONS III.....</b>	<b>67-70</b>
<b>Drug Abuse: The Next Generation</b>	
<b>ORAL COMMUNICATIONS IV .....</b>	<b>71-75</b>
<b>Form and Function</b>	
<b>ORAL COMMUNICATIONS V.....</b>	<b>75-79</b>
<b>There's no Substitute for Treatment</b>	
<b>ORAL COMMUNICATIONS VI .....</b>	<b>79-83</b>
<b>Drug Abuse in Adolescents</b>	
<b>ORAL COMMUNICATIONS VII .....</b>	<b>83-85</b>
<b>HIV and Hepatitis</b>	
<b>ORAL COMMUNICATIONS VIII.....</b>	<b>86-89</b>
<b>Where There's Smoke, There's Science</b>	
<b>ORAL COMMUNICATIONS IX .....</b>	<b>89-93</b>
<b>Strike up the Glands</b>	
<b>ORAL COMMUNICATIONS X.....</b>	<b>93-97</b>
<b>Role of Sex on Treatment Outcome</b>	
<b>ORAL COMMUNICATIONS XI .....</b>	<b>98-100</b>
<b>Risk Factors for Substance Abuse</b>	
<b>ORAL COMMUNICATIONS XII .....</b>	<b>101-105</b>
<b>Into the Brains of Primates</b>	
<b>ORAL COMMUNICATIONS XIII .....</b>	<b>106-110</b>
<b>The Downers Update</b>	
<b>ORAL COMMUNICATIONS XIV .....</b>	<b>110-112</b>
<b>Multifaces of Naltrexone</b>	

<b>ORAL COMMUNICATIONS XV</b> .....	<b>112-116</b>
<b>Agonist Treatment for Cocaine Dependence</b>	
<b>ORAL COMMUNICATIONS XVI</b> .....	<b>116-117</b>
<b>Cellular and Molecular Drug Effects</b>	
<b>ORAL COMMUNICATIONS XVII</b> .....	<b>118-120</b>
<b>Double Trouble</b>	
<b>ORAL COMMUNICATIONS XVIII</b> .....	<b>121-124</b>
<b>Pot Pourri</b>	
<b>ORAL COMMUNICATIONS XIX</b> .....	<b>125-128</b>
<b>Neurobiology</b>	
<b>ORAL COMMUNICATIONS XX</b> .....	<b>128-132</b>
<b>Stimulants: The Agonist and Ecstasy</b>	
<b>POSTER SESSION I</b> .....	<b>133-185</b>
<b>Personality and Disorders</b>	
<b>Impulsivity, Anger, Domestic Violence</b>	
<b>Vulnerable Populations and Drug Abuse</b>	
<b>Pharmacokinetics</b>	
<b>Methadone, LAAM, Buprenorphine</b>	
<b>Cocaine: Pharmacotherapy</b>	
<b>Cocaine/Opioid Interactions</b>	
<b>Opioids: Behavior</b>	
<b>Benzodiazepines and Inhalants</b>	
<b>POSTER SESSION II</b> .....	<b>186-233</b>
<b>Adolescents</b>	
<b>Nicotine and Caffeine</b>	
<b>Immune System</b>	
<b>Neuroendocrines and Stress</b>	
<b>Cocaine: Genetics, Neurophysiology</b>	
<b>Cocaine: Psychosocial Treatment</b>	
<b>Employment Issues</b>	
<b>Opioid Withdrawal</b>	
<b>Pain and Analgesia</b>	
<b>POSTER SESSION III</b> .....	<b>234-279</b>
<b>Amphetamines</b>	
<b>Imaging</b>	
<b>Cocaine: Cardiovascular Effects</b>	
<b>Opioid Receptors</b>	
<b>Cocaine: Dopamine and Serotonin</b>	
<b>Comorbidity</b>	
<b>Gender</b>	
<b>Women</b>	
<b>Epidemiology</b>	

<b>POSTER SESSION IV .....</b>	<b>281-329</b>
<b>Cannabinoids and THC</b>	
<b>NMDA/Sigma Receptors, Ibogaine</b>	
<b>Seizure and Locomotor Activity</b>	
<b>Perinatal Exposure and Development</b>	
<b>Pregnancy</b>	
<b>Methods and Assessment</b>	
<b>Opioids: Psychosocial Treatment</b>	
<b>HIV/AIDS</b>	

<b>LATE ABSTRACTS .....</b>	<b>330-331</b>
-----------------------------	----------------

**ANNUAL REPORTS**

<b>Biological Evaluation of Compounds for Their Physical Dependence Potential and Abuse Liability. XXIII. Drug Evaluation Committee of the College on Problems of Drug Dependence (1999).....</b>	<b>332-345</b>
<i>A. E. Jacobson</i>	
<b>Dependence Studies of New Compounds in the Rhesus Monkey, Rat, and Mouse (1999).....</b>	<b>346-404</b>
<i>M.D. Aceto, E.R. Bowman, L.S. Harris, and E.L. May</i>	
<b>Evaluation of New Compounds for Opioid Activity (1999).....</b>	<b>405-422</b>
<i>J.W. Woods, G.W. Winger, J.R. Traynor, M.-C. Ko, and F. Medzihradsky</i>	
<b>Progress Report from the Testing Program for Stimulant and Depressant Drugs (1999).....</b>	<b>423-433</b>
<i>C.P. France, L.R. Gerak, J.W. Rowlett, W.L. Woolverton, G. Winger, and R.J. Briscoe</i>	

<b>AUTHOR INDEX.....</b>	<b>434-448</b>
--------------------------	----------------

<b>SUBJECT INDEX .....</b>	<b>449-476</b>
----------------------------	----------------